Proteonomix has announced the formation of a wholly owned subsidiary, Proteonomix Regenerative Translational Medicine Institute (PRTMI), to deliver promising new stem cell and cellular therapy applications.
PRTMI will focus specifically on the translation of promising research in stem cell biology and cellular therapy to develop clinical applications of regenerative medicine.
The objective of PRTMI will be to undertake preclinical and clinical trials in regenerative medicine to deliver cutting-edge therapies, overcoming delays caused by non-clinical considerations.
The institute will develop clinical protocols, organise manufacturing of cellular products for clinical use, and monitor compliance of clinical trials conducted by PRTMI with government and regulatory bodies.
PRTMI will seek to acquire and strategically align itself with proven products in the marketplace that may provide cutting edge-strategies when combined with the regenerative medicine therapies developed by parent company Proteonomix.